Aga nanotech

AGA Nanotech is a biotechnology company focused on combating antimicrobial resistance (AMR) through the development of its patented antimicrobial delivery system, Battlestar. The technology utilizes Poly(lactic-co-glycolic acid) (PLGA) microspheres to provide a controlled and sustained release of oxidative biocides, specifically peracetic acid and hydrogen peroxide, directly at the site of an infection. Unlike traditional antibiotic treatments, this non-antibiotic approach generates these biocides in situ at a near-neutral pH, which maintains broad-spectrum efficacy against bacteria, fungi, viruses, and spores while minimizing cytotoxicity and supporting tissue repair.

This innovation addresses the critical global health challenge of AMR, which threatens modern medical procedures such as surgeries and transplants by reducing the effectiveness of conventional antibiotics. The technology's ability to combat infections without fostering resistance makes it highly relevant for applications in wound care and other clinical settings. The company's progress has been recognized with industry awards, including the 2025 EWMA Innovation Competition Prize, and it actively collaborates with research institutions and clinical partners to advance its solutions toward commercialization and improved patient outcomes.